1. This article discusses the use of CRISPR-Cas9 gene editing technology to modify CAR-T cells.
2. The authors demonstrate that multiplex gene editing can be achieved in CAR-T cells using this technology.
3. The results suggest that CRISPR-Cas9 could be a useful tool for manipulating CAR-T cells for therapeutic applications.
The article is generally reliable and trustworthy, as it is published in a reputable journal (Cell Research) and has been peer reviewed by experts in the field. The authors provide evidence to support their claims, such as data from experiments conducted with CRISPR-Cas9 gene editing technology on CAR-T cells. However, there are some potential biases that should be noted. For example, the authors do not discuss any potential risks associated with using this technology, nor do they explore any counterarguments or alternative approaches to manipulating CAR-T cells for therapeutic applications. Additionally, the article does not present both sides of the argument equally; instead, it focuses primarily on the benefits of using CRISPR-Cas9 gene editing technology without exploring any potential drawbacks or limitations of this approach.